Name: the lambda select cii mutation detection system
Uploaded: 2018-04-26T15:00:00.000+00:00
Duration: 7 min 8 s
Description: Watch this Scientific Journal Video about The Lambda Select cII Mutation Detection System at JoVE.com

すべての同僚の貢献と (説明のため) この原稿に呼ばれている、結果が私たちの元の研究に協力したいと思います。作家の作品は、国立歯科・頭蓋顔面研究、国立衛生研究所 (1R01DE026043) ab の AB (California Tobacco-Related 病研究プログラムの大学からの補助金によってサポートされてTRDRP-26IR-0015) および ST (TRDRP-25IP-0001)。研究のスポンサーには、研究デザイン、データ収集、データ分析、データ解釈、レポートの執筆、出版のために提出する決定の役割はなかった。

すべての著者は利益相反を宣言しません。

Λ 選択cIIアッセイは、3BB の齧歯動物の臓器・組織由来細胞のゲノム DNA から回復したcII遺伝子変異の検出に使用されます。これらの形質転換動物ゲノムには染色体統合 λLIZ シャトル ベクトルは、 cIIを運ぶ複数タンデム コピーが含まれます (294 bp) とラッチ(1,080 bp) 遺伝子変異レポーター遺伝子1,2,</su...

トランスジェニック動物モデルおよび突然変異検出システムの広い範囲は、哺乳類細胞における発がん性物質の変異原性試験のために開発されています。これらの大きなブルー (以下 bb) トランスジェニック マウスと λ 選択cII変異検出システムで採用されている変異原性実験のためこのグループは、多くの他研究グループ世界中1,の2、 3,4,5,6,7,8,9。過去 16 年間、これらのトランスジェニック動物を用いた化学的および/または物理的な剤の変異原性の効果を調べたか、対応する胚性線維芽細胞培養テスト混合物と扱われ、その後の分析、λ 選択cIIアッセイおよび DNA の配列、それぞれ10、11,12,の13,14によってcII遺伝子の遺伝子型と表現型,15,16,17,18,19,20,21,22,23,24. これらのトランスジェニック動物のゲノムに複数コピー頭-尾コンカテマー1,2,25, 染色体 4 統合バクテリオファージ λ シャトル ベクトル (λLIZ) が含まれています。ΛLIZ シャトルベクターを運ぶ 2 つの変異レポーター遺伝子、すなわち、ラッチとcII遺伝子1,2,25,26,27、 28,29,30,31,32,33,34,35,36、 37,38,39,40,41,42,43,44,45,46,47. λ 選択cIIアッセイに基づいて λLIZ シャトル ベクトルのトランスジェニック動物1,2,25 の臓器・組織由来細胞のゲノム DNA からの回復.回復 λLIZ シャトル ベクトル、インジケーター ホスト大腸菌に感染可能な λ ファージの頭にパッケージ化されます。その後、感染した細菌は、得点とcII遺伝子1,3における変異解析を可能にする選択的な条件のもとで栽培しています。
ここ、体外治療トランスジェニック動物の細胞・臓器からゲノム DNA の隔離から成っている λ 選択cIIの試金のための詳しいプロトコルについて述べる/シャトル生体内でλLIZ の化合物は、取得テスト ベクトルgenomic DNA から、バクテリオファージ、 cIIの同定とホストエシェリヒア属大腸菌の感染感染 λ ファージにベクトルの包装- cIIの突然変異頻度を決定する選択的な条件の下で突然変異体とCII変異スペクトルを確立する dna 塩基配列解析。トランスジェニック マウス ・ ラット細胞培養体外興味の化学/物理エージェントに適用できるプロトコルまたは対応する動物の組織/臓器治療体内テスト化学/エージェント1、 2,4,48,49,50,51,52。Λ 選択cIIアッセイの図式を図 1に示します。

<table><tbody><tr><td>Agar</td><td>MO Bio Laboratories, Inc.</td><td>12112-05</td><td>Bacteriological grade</td></tr><tr><td>BigDye Terminator v3.1 Cycle Sequencing Kit</td><td>Thermo Fisher Scientific</td><td>4337455</td><td>None</td></tr><tr><td>Casein Peptone</td><td>Alfa Aesar</td><td>H26557</td><td>None</td></tr><tr><td>Gelatine</td><td>J. T. Baker</td><td>2124-01</td><td>Powder</td></tr><tr><td>Glycerol</td><td>Fisher Scientific</td><td>BP 229-1 / M-13750</td><td>None</td></tr><tr><td>LB Agar</td><td>Fisher Scientific</td><td>BP 9724-500</td><td>None</td></tr><tr><td>QIAquick PCR purification kit</td><td>Qiagen</td><td>8104</td><td>50 PCR purification reactions</td></tr><tr><td>Sodium Acetate Trihydrate</td><td>Fisher Scientific</td><td>M-15756</td><td>None</td></tr><tr><td>&lt;em&gt;Taq5000&lt;/em&gt; DNA Polymerase&amp;nbsp;</td><td>Qiagen</td><td>201207</td><td>None</td></tr><tr><td>Thiamine Hydrochloride</td><td>Macron Fine Chemicals</td><td>2722-57</td><td>None</td></tr><tr><td>Transpack Packaging Extract</td><td>Stratagene Corp., Acquired by BioReliance | Sigma-Aldrich Corp.</td><td>200223</td><td>50 packaging reactions</td></tr><tr><td>Tris Base</td><td>Fisher Scientific</td><td>BP 152-1 / EC 201-064-4</td><td>None</td></tr><tr><td>Trypton</td><td>Biosciences</td><td>RC-110</td><td>None</td></tr></tbody></table>

the lambda select cii mutation detection system

トランスジェニック動物モデルおよび突然変異検出システムの数は、哺乳類細胞における発がん性物質の変異原性試験のために開発されています。これらのトランスジェニック マウスとラムダ (λ) の選択cII変異検出システム世界中の多くの研究グループによって変異原性実験のため採用されています。ここでは、ラムダを選択cII突然変異試験は、トランスジェニック マウス/ラットの培養細胞に適用することができるための詳しいプロトコルについて述べるまたは興味の化学/物理エージェントに対応する動物が扱われます。プロトコルは、次の手順で構成されます: (1) 分離細胞からゲノム dna やトランスジェニック動物の臓器・組織生体外でまたは生体内で、それぞれで治療テスト混合物;(ゲノム DNA からの (すなわち、 cII遺伝子) の変異レポーター遺伝子を運ぶラムダ シャトルベクターの回復 2)(伝染性のバクテリオファージに救助されたベクトルの包装 3)(4) ホストの細菌に感染して誘導cII突然変異の伝播を許可する選択的な条件下で培養(5) 得点cII-変異体と DNA シーケンスをそれぞれcII突然変異頻度および突然変異スペクトルを分析します。

データ ディストリビューションによってパラメトリックまたはノンパラのテストを使用して、処置および制御グループ (すなわち、自発の突然変異体の周波数対誘導) のcIIの突然変異頻度の違いの重要性を判断します.誘導cII変異周波数別の治療グループ間での比較が行われます各種 (一対)、適用可能な統計的テスト。Χ2テストや分散分析 (...

Watch this Scientific Journal Video about The Lambda Select cII Mutation Detection System at JoVE.com

The Lambda Select cII Mutation Detection System

ラムダを選択cII変異検出システム

トランスジェニックげっ歯類の培養細胞でラムダを選択cII突然変異試験または興味の化学/物理エージェントで治療対応する動物のための詳しいプロトコルについて述べる。このアプローチは、哺乳類細胞における発がん性物質の変異原性試験のため広く使用されています。

A number of transgenic animal models and mutation detection systems have been developed for mutagenicity testing of carcinogens in mammalian cells. Of ...

the-lambda-select-cii-mutation-detection-system

Research

JoVE Journal

Immunology and Infection

The Lambda Select cII Mutation Detection System

7.8K ビュー.  University of Southern California. トランスジェニックげっ歯類の培養細胞でラムダを選択cII突然変異試験または興味の化学/物理エージェントで治療対応する動物のための詳しいプロトコルについて述べる。このアプローチは、哺乳類細胞における発がん性物質の変異原性試験のため広く使用されています。

ビデオ: The Lambda Select cII Mutation Detection System

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Accurate detection and identification of low frequency mutations can be problematic when assessing residual disease after therapy, screening for emerging resistance mutations during therapy, or when patients have few circulating tumor cells. Wild-type blocking PCR followed by sequencing analysis offers high sensitivity, flexibility, and simplicity as a methodology for detecting these low frequency mutations. By adding a custom designed locked nucleic acid oligonucleotide to a new or previously established conventional PCR based sequencing assay, sensitivities of approximately 1 mutant allele in a background of 1,000 WT alleles can be achieved (1:1,000). Sequencing artifacts associated with deamination events commonly found in formalin fixed paraffin embedded tissues can be partially remedied by the use of uracil DNA glycosylase during extraction steps. The optimized protocol here is specific for detecting MYD88 mutation, but can serve as a template to design any WTB-PCR assay. Advantages of the WTB-PCR assay over other commonly utilized assays for the detection of low frequency mutations including allele specific PCR and real-time quantitative PCR include fewer occurrences of false positives, greater flexibility and ease of implementation, and the ability to detect both known and unknown mutations.

Wild-type blocking PCR followed by direct sequencing offers a highly sensitive method of detection for low frequency somatic mutations in a variety of sample types.

低周波体細胞変異の検出のための高感度な方法として直接配列決定と組み合わせるPCRをブロックする野生型

Accurate detection and identification of low frequency mutations can be problematic when assessing residual disease after therapy, screening for emerging ...

遺伝学

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

The analysis of circulating tumor DNA (ctDNA) using next-generation sequencing (NGS) has become a valuable tool for the development of clinical oncology. However, the application of this method is challenging due to its low sensitivity in analyzing the trace amount of ctDNA in the blood. Furthermore, the method may generate false positive and negative results from this sequencing and subsequent analysis. To improve the feasibility and reliability of ctDNA detection in the clinic, here we present a technique which enriches rare mutations for sequencing, Enrich Rare Mutation Sequencing (ER-Seq). ER-Seq can distinguish a single mutation out of 1 x 107 wild-type nucleotides, which makes it a promising tool to detect extremely low frequency genetic alterations and thus will be very useful in studying disease heterogenicity. By virtue of the unique sequencing adapter&#39;s ligation, this method enables an efficient recovery of ctDNA molecules, while at the same time correcting for errors bidirectionally (sense and antisense). Our selection of 1021 kb probes enriches the measurement of target regions that cover over 95% of the tumor-related driver mutations in 12 tumors. This cost-effective and universal method enables a uniquely successful accumulation of genetic data. After efficiently filtering out background error, ER-seq can precisely detect rare mutations. Using a case study, we present a detailed protocol demonstrating probe design, library construction, and target DNA capture methodologies, while also including the data analysis workflow. The process to carry out this method typically takes 1-2 days.

This manuscript describes a technique for detecting mutations of low frequency in ctDNA, ER-Seq. This method is differentiated by its unique use of two-directional error correction, a special background filter, and efficient molecular acquirement.

次世代シーケンシングによる葉緑体の稀な遺伝子変異の検出

The analysis of circulating tumor DNA (ctDNA) using next-generation sequencing (NGS) has become a valuable tool for the development of clinical oncology. ...

がん研究

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Conventional next-generation sequencing techniques (NGS) have allowed for immense genomic characterization for over a decade. Specifically, NGS has been used to analyze the spectrum of clonal mutations in malignancy. Though far more efficient than traditional Sanger methods, NGS struggles with identifying rare clonal and subclonal mutations due to its high error rate of ~0.5&#8211;2.0%. Thus, standard NGS has a limit of detection for mutations that are &#62;0.02 variant allele fraction (VAF). While the clinical significance for mutations this rare in patients without known disease remains unclear, patients treated for leukemia have significantly improved outcomes when residual disease is &#60;0.0001 by flow cytometry. In order to mitigate this artefactual background of NGS, numerous methods have been developed. Here we describe a method for Error-corrected DNA and RNA Sequencing (ECS), which involves tagging individual molecules with both a 16 bp random index for error-correction and an 8 bp patient-specific index for multiplexing. Our method can detect and track clonal mutations at variant allele fractions (VAFs) two orders of magnitude lower than the detection limit of NGS and as rare as 0.0001 VAF.

Next-generation sequencing (NGS) is a powerful tool for genomic characterization that is limited by the high error rate of the platform (~0.5&#8211;2.0%). We describe our methods of error-corrected sequencing that allow us to obviate the NGS error rate and detect mutations at variant allele fractions as rare as 0.0001.

エラー修正 DNA ・ RNA シーケンスを用いた珍しいイベント検出

Conventional next-generation sequencing techniques (NGS) have allowed for immense genomic characterization for over a decade. Specifically, NGS has been ...

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive quantitative polymerase chain reaction (PCR) method based on sample fractionation into thousands of nano-sized water-in-oil individual reactions. Recently, ddPCR has become one of the most accurate and sensitive tools for circulating tumor DNA (ctDNA) detection. One of the major limitations of the standard ddPCR technique is the restricted number of mutations that can be screened per reaction, as specific hydrolysis probes recognizing each possible allelic version are required. An alternative methodology, the drop-off ddPCR, increases throughput, since it requires only a single pair of probes to detect and quantify potentially all genetic alterations in the targeted region. Drop-off ddPCR displays comparable sensitivity to conventional ddPCR assays with the advantage of detecting a greater number of mutations in a single reaction. It is cost-effective, conserves precious sample material, and can also be used as a discovery tool when mutations are not known a priori.

Here, we present a protocol to accurately quantify multiple genetic alterations of a target region in a single reaction using drop-off ddPCR and a unique pair of hydrolysis probes.

ホット スポット領域の変異の包括的かつ同時検出のための単一液滴デジタル ポリメラーゼの連鎖反応

Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive quantitative polymerase chain reaction (PCR) method based on sample fractionation ...

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

The epigenetic transcription regulation mediated by 5-methylcytosine (5mC) has played a critical role in eukaryotic development. Demethylation of these epigenetic marks is accomplished by sequential oxidation by ten-eleven translocation dioxygenases (TET1-3), followed by the thymine-DNA glycosylase-dependent base excision repair. Inactivation of the TET2 gene due to genetic mutations or by other epigenetic mechanisms is associated with a poor prognosis in patients with diverse cancers, especially hematopoietic malignancies. Here, we describe an efficient single step purification of enzymatically active untagged human TET2 dioxygenase using cation exchange chromatography. We further provide a liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach that can separate and quantify the four normal DNA bases (A, T, G, and C), as well as the four modified cytosine bases (5-methyl, 5-hydroxymethyl, 5-formyl, and 5-carboxyl). This assay can be used to evaluate the activity of wild type and mutant TET2 dioxygenases.

Here, we present a protocol for an efficient single step purification of the active untagged human ten-eleven translocation-2 (TET2) 5-methylcytosine dioxygenase using ion-exchange chromatography and its assay using a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based approach.

10-11 転流 2 5-メチルシトシン ジオキシゲナーゼの LC MS/MS による分析法の開発や効率的に精製

The epigenetic transcription regulation mediated by 5-methylcytosine (5mC) has played a critical role in eukaryotic development. Demethylation of these ...

生化学

qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes

Killer cell immunoglobulin-like receptors (KIRs) are a set of inhibitory and activating immune receptors, on natural killer (NK) and T cells, encoded by a polymorphic cluster of genes on chromosome 19. Their best-characterized ligands are the human leukocyte antigen (HLA) molecules that are encoded within the major histocompatibility complex (MHC) locus on chromosome 6. There is substantial evidence that they play a significant role in immunity, reproduction, and transplantation, making it crucial to have techniques that can accurately genotype them. However, high-sequence homology, as well as allelic and copy number variation, make it difficult to design methods that can accurately and efficiently genotype all KIR genes. Traditional methods are usually limited in the resolution of data obtained, throughput, cost-effectiveness, and the time taken for setting up and running the experiments. We describe a method called quantitative KIR semi-automated typing (qKAT), which is a high-throughput multiplex real-time polymerase chain reaction method that can determine the gene copy numbers for all genes in the KIR locus. qKAT is a simple high-throughput method that can provide high-resolution KIR copy number data, which can be further used to infer the variations in the structurally polymorphic haplotypes that encompass them. This copy number and haplotype data can be beneficial for studies on large-scale disease associations, population genetics, as well as investigations on expression and functional interactions between KIR and HLA.

Quantitative killer cell immunoglobulin-like receptor (KIR) semi-automated typing (qKAT) is a simple, high-throughput, and cost-effective method to copy number type KIR genes for their application in population and disease association studies.

qKAT: キラー細胞免疫グロブリン様受容体遺伝子の定量的半自動化された入力

Killer cell immunoglobulin-like receptors (KIRs) are a set of inhibitory and activating immune receptors, on natural killer (NK) and T cells, encoded by a ...

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Complications associated with upfront and repeat surgical tissue sampling present the need for minimally invasive platforms capable of molecular sub-classification and temporal monitoring of tumor response to therapy. Here, we describe our dPCR-based method for the detection of tumor somatic mutations in cell free DNA (cfDNA), readily available in&#160;patient biofluids. Although limited in the number of mutations that can be tested for in each assay, this method provides a high level of sensitivity and specificity. Monitoring of mutation abundance, as calculated by MAF, allows for the evaluation of tumor response to therapy, thereby providing a much-needed supplement to radiographic imaging.

Here, we present a protocol to detect tumor somatic mutations in circulating DNA present in patient biological fluids (biofluids). Our droplet digital polymerase chain reaction (dPCR)-based method enables quantification of the tumor mutation allelic frequency (MAF), facilitating a minimally invasive complement to diagnosis and temporal monitoring of tumor response.

患者の生体流体における腫瘍関連循環DNAの検出とモニタリング

Complications associated with upfront and repeat surgical tissue sampling present the need for minimally invasive platforms capable of molecular ...

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

In recent years, it has become apparent that genomic instability is tightly related to many developmental disorders, cancers, and aging. Given that stem cells are responsible for ensuring tissue homeostasis and repair throughout life, it is reasonable to hypothesize that the stem cell population is critical for preserving genomic integrity of tissues. Therefore, significant interest has arisen in assessing the impact of endogenous and environmental factors on genomic integrity in stem cells and their progeny, aiming to understand the etiology of stem-cell based diseases.
LacI transgenic mice carry a recoverable &#955;&#160;phage vector encoding the LacI reporter system, in which the LacI gene serves as the mutation reporter. The result of a mutated LacI gene is the production of &#946;-galactosidase that cleaves a chromogenic substrate, turning it blue. The LacI reporter system is carried in all cells, including stem/progenitor cells and can easily be recovered and used to subsequently infect E. coli. After incubating infected E. coli on agarose that contains the correct substrate, plaques can be scored; blue plaques indicate a mutant LacI gene, while clear plaques harbor wild-type. The frequency of blue (among clear) plaques indicates the mutant frequency in the original cell population the DNA was extracted from. Sequencing the mutant LacI gene will show the location of the mutations in the gene and the type of mutation.
The LacI transgenic mouse model is well-established as an in vivo mutagenesis assay. Moreover, the mice and the reagents for the assay are commercially available. Here we describe in detail how this model can be adapted to measure the frequency of spontaneously occurring DNA mutants in stem cell-enriched Lin-IL7R-Sca-1+cKit++(LSK) cells and other subpopulations of the hematopoietic system.

Here we describe an in vivo mutagenesis assay for small numbers of purified hematopoietic cells using the LacI transgenic mouse model.&#160;The LacI gene can be isolated to determine the frequency, location, and type of DNA mutants&#160;spontaneously arisen or after exposure to genotoxins.

精製造血幹細胞/前駆細胞のDNAの変異を特定する

In recent years, it has become apparent that genomic instability is tightly related to many developmental disorders, cancers, and aging. Given that stem ...

免疫・感染学

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Genome-scale interrogation of gene function using RNA interference (RNAi) holds tremendous promise for the rapid identification of chemically tractable cancer cell vulnerabilities. Limiting the potential of this technology is the inability to rapidly delineate the mechanistic basis of phenotypic outcomes and thus inform the development of molecularly targeted therapeutic strategies. We outline here methods to deconstruct cellular phenotypes induced by RNAi-mediated gene targeting using multiplexed reporter systems that allow monitoring of key cancer cell-associated processes. This high-content screening methodology is versatile and can be readily adapted for the screening of other types of large molecular libraries.

Achieving a systems level understanding of cellular processes is a goal of modern-day cell biology. We describe here strategies for multiplexing luciferase reporters of various cellular function end-points to interrogate gene function using genome-scale RNAi libraries.

培養細胞における癌関連シグナル伝達を問い合わせるための多重ルシフェラーゼベースのスクリーニング·プラットフォーム

Genome-scale interrogation of gene function using RNA interference (RNAi)  holds tremendous promise for the rapid identification of chemically tractable  ...

医学

Naked-Eye Detection of Rare Point Mutations in DNA

The protocol describes a naked-eye colorimetric test for the detection of somatic point mutations in an excess of wild type DNA. The future foreseen application of the method is the identification of rare mutations in circulating cell-free DNA from liquid biopsies, with a relevance in cancer diagnostics and stratification of oncological patients for personalized therapy. As a proof of concept, the test has been designed to detect the BRAFV600E mutation in the BRAF gene, which is important to identify the sub-group of melanoma patients that can benefit from targeted therapies with BRAF inhibitors. However, this colorimetric test can be easily generalized to other somatic mutations of clinical relevance due to the use of universal detection probes, thus providing strong potential in oncological diagnostics.
The test detects 0.5% of BRAFV600E in an excess of BRAFWT DNA, which matches the sensitivity of some commercial instrumental assays. Such sensitivity is clinically relevant for diagnostic purposes, allowing the early identification of drug-sensitive patients. In contrast to commercial assays based on real-time PCR, this test requires minimal instrumentation and processing, as it can be performed on DNA amplified with a standard PCR (or isothermal techniques) and provides a naked-eye readout with a one-tube reaction of a few steps in only one hour. At present, the test has been used only on synthetic DNA samples. However, the latter have been designed to mimic a real sample amplified from circulating cell-free DNA, to favor the translation of the test to clinical diagnostics.

This protocol permits the naked-eye identification of point mutated DNA in a 200-fold excess of wild type DNA molecules, by exploiting gold nanoparticles and paramagnetic microparticles.

The protocol describes a naked-eye colorimetric test for the detection of somatic point mutations in an excess of wild type DNA. The future foreseen ...

ラムダを選択cII変異検出システム

要約

さらに動画を探す

この動画の章

低周波体細胞変異の検出のための高感度な方法として直接配列決定と組み合わせるPCRをブロックする野生型

次世代シーケンシングによる葉緑体の稀な遺伝子変異の検出

エラー修正 DNA ・ RNA シーケンスを用いた珍しいイベント検出

ホットスポット領域の変異の包括的かつ同時検出のための単一液滴デジタルポリメラーゼの連鎖反応

10-11 転流 2 5-メチルシトシンジオキシゲナーゼの LC MS/MS による分析法の開発や効率的に精製

qKAT: キラー細胞免疫グロブリン様受容体遺伝子の定量的半自動化された入力

患者の生体流体における腫瘍関連循環DNAの検出とモニタリング

精製造血幹細胞/前駆細胞のDNAの変異を特定する

培養細胞における癌関連シグナル伝達を問い合わせるための多重ルシフェラーゼベースのスクリーニング·プラットフォーム

Naked-Eye Detection of Rare Point Mutations in DNA

ラムダを選択cII変異検出システム

要約

さらに動画を探す

この動画の章

低周波体細胞変異の検出のための高感度な方法として直接配列決定と組み合わせるPCRをブロックする野生型

次世代シーケンシングによる葉緑体の稀な遺伝子変異の検出

エラー修正 DNA ・ RNA シーケンスを用いた珍しいイベント検出

ホット スポット領域の変異の包括的かつ同時検出のための単一液滴デジタル ポリメラーゼの連鎖反応

10-11 転流 2 5-メチルシトシン ジオキシゲナーゼの LC MS/MS による分析法の開発や効率的に精製

qKAT: キラー細胞免疫グロブリン様受容体遺伝子の定量的半自動化された入力

患者の生体流体における腫瘍関連循環DNAの検出とモニタリング

精製造血幹細胞/前駆細胞のDNAの変異を特定する

培養細胞における癌関連シグナル伝達を問い合わせるための多重ルシフェラーゼベースのスクリーニング·プラットフォーム

Naked-Eye Detection of Rare Point Mutations in DNA

ホットスポット領域の変異の包括的かつ同時検出のための単一液滴デジタルポリメラーゼの連鎖反応

10-11 転流 2 5-メチルシトシンジオキシゲナーゼの LC MS/MS による分析法の開発や効率的に精製